July 29, 2016 4:28 PM ET

Biotechnology

Company Overview of Pharmacyclics LLC

Company Overview

Pharmacyclics LLC focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a first-in-class, oral, once-daily, single-agent therapy used for the treatment of patients with: chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17; mantle cell lymphoma who have received at least one prior therapy; and all lines of waldenström's macroglobulinemia (WM). Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under phase I, II, III clinical trials for the treatment ...

999 East Arques Avenue

Sunnyvale, CA 94085

United States

Founded in 1991

634 Employees

Phone:

408-774-0330

Fax:

408-774-0340

Key Executives for Pharmacyclics LLC

Chairman and Chief Executive Officer
Age: 72
Chief Operating Officer
Age: 46
Executive Vice President of Corporate Affairs
Age: 53
Senior Vice President of Global Quality and Training
Age: 51
Senior Vice President of Regulatory
Age: 45
Compensation as of Fiscal Year 2016.

Pharmacyclics LLC Key Developments

Pharmacyclics LLC Presents at ChinaBio Leadership Retreat 2015, Oct-22-2015

Pharmacyclics LLC Presents at ChinaBio Leadership Retreat 2015, Oct-22-2015 . Venue: Changshu, China.

Pharmacyclics LLC and Janssen Biotech Inc. Announce Submission of a Supplemental New Drug Application for IMBRUVICA (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia

AbbVie announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on the randomized, multi-center, open-label Phase III RESONATETM-2 (PCYC-1115) trial assessing the use of IMBRUVICA® (ibrutinib) versus chlorambucil in treatment-naive chronic lymphocytic leukemia (CLL) patients aged 65 years or older. AbbVie announced top-line findings from the trial in June 2015 showing that IMBRUVICA improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naive patients with CLL. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc. IMBRUVICA is currently approved for the treatment of patients with CLL who have received at least one prior therapy and CLL patients (including treatment-naive) who have del 17p, a genetic aberration that occurs when part of chromosome 17, the location of the tumor suppressor gene p53, has been lost or deleted. The data have been submitted for publication in a peer-reviewed journal and presentation at an upcoming medical conference.

Pharmacyclics Announces Positive Top-Line Results from Phase III trial

Pharmacyclics has announced positive top-line results from a Phase III trial (RESONATE-2) investigating the safety and efficacy of Imbruvica (ibrutinib; 420 milligrammes) versus chlorambucil in treatment-nave chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) patients aged 65 years or older. The global, randomised, multi-centre, open-label study enrolled 269 patients and met its primary endpoint as measured by an improvement in progression-free survival (PFS), as well as multiple secondary endpoints of overall survival (OS)and an overall response rate (ORR) with Imbruvica compared with chlorambucil. The trial was designed under a special protocol assessment (SPA) agreement with the US FDA. Detailed results from the trial will be published in a peer-reviewed journal and presented at an upcoming medical meeting. The positive clinical trial results mark a milestone for AbbVie and its partner Janssen Biotech (subsidiary of Johnson & Johnson; J&J, US), as it is first to demonstrate head-to-head safety and efficacy versus chemotherapy in the clinical programme. Pharmacyclics' head of oncology Danelle James noted the transformative nature of the study that could replace cytotoxic chemotherapy as a first-line treatment for CLL in older patients with orally administered Imbruvica. The promising oncology drug is currently approved for the second-line treatment of CLL, or first-line treatment of CLL in patients with a 17p deletion, among other types of B-cell malignancies, such as Waldenstrom's acroglobulinaemia and mantle cell lymphoma. Expansion of the breakthrough therapy-designated drug's label to the first-line CLL setting will be good news for AbbVie and J&J; the partners share in the commercialisation of the drug in the United States. J&J retains rights for Imbruvica outside the US. The drug is being investigated as monotherapy or a combination regimen for a variety of haematological malignancies across 13 Phase III trials and 67 registered clinical trials in the US. AbbVie has acquired Pharmacyclics in 2015 for USD 21 billion, gaining access to Imbruvica that generated USD 548 million in global sales in 2014, with annual US sales anticipated to reach USD 1 billion this year 2015.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Pharmacyclics LLC, please visit www.pharmacyclics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.